SLC5A2 and coronary artery disorder: The presence of established cardiovascular disease was evident with 11.1% in the SGLT2 inhibitor group versus 11% in the non-SGLT2 inhibitor group having ischemic heart disease and 2.6% with cerebrovascular disease.